EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

ACE trial design: Equol targeting estrogen receptor‐β in vascular and cognitive aging

Akira Sekikawa iD, Whitney Wharton, Cristina Murray-Krezan, Minjie Wu, Yuefang Chang, Beth E Snitz, Mindy Coccari, Shaolin Yang, Monica L Love, Deborah Cusick, Rongrong Wang, Mengyi Li und 13 weitere

Alzheimer's & Dementia: Translational Research & Clinical Interventions · 2025-07 · 11 (3)

DOI: 10.1002/trc2.70144 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia: Translational Research & Clinical Interventions, online erschienen am 18.08.2025. Verfasst von Akira Sekikawa und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology School of Public Health University of Pittsburgh Pittsburgh Pennsylvania USA. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, NIDDK NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Equol, a gut microbiome‐derived metabolite of soy isoflavone daidzein, functions as a selective estrogen receptor beta (ERβ) agonist. In preclinical studies, it has demonstrated vascular protective and antioxidant effects, with emerging evidence suggesting potential neuroprotective properties. However, its role in preventing vascular aging and cognitive decline in humans remains unexplored. The Arterial Stiffness, Cognition, and Equol (ACE) trial investigates whether daily equol supplementation can slow the progression of arterial stiffness, brain white matter lesions, and cognitive decline in older adults without dementia. METHODS ACE is a multicenter, randomized, double‐blind, placebo‐controlled clinical trial conducted at the University of Pittsburgh, Wake Forest University, and Emory University. Community‐dwelling adults aged 65 to 85 years without dementia were enrolled and randomized 1:1 to receive either 10 mg/day of equol or placebo for 24 months. The primary outcome is arterial stiffness assessed by carotid‐femoral pulse wave velocity. Secondary outcomes include white matter lesions detected on the brain magnetic resonance imaging and cognitive function as assessed by the Preclinical Alzheimer Cognitive Composite. Power calculations were based on a planned sample size of 400 participants, accounting for an anticipated 20% attrition rate. RESULTS A total of 1783 individuals were pre‐screened, and 764 underwent in‐person eligibility assessment. Of these, 369 participants were randomized into two groups: Arm A ( n = 185) and Arm B ( n = 184). The randomized sample self‐reported as 52% women and 22% Black/African American participants. Baseline demographic and clinical characteristics were well balanced between the two arms, indicating successful randomization. DISCUSSION ACE successfully enrolled a racially diverse population of older adults and achieved near‐target recruitment. ACE is the first large‐scale trial to evaluate whether equol, a selective ERβ agonist, can impact vascular and cognitive aging, paving the way for precision nutrition strategies in dementia prevention. Highlights We detail the first randomized controlled trial of equol, an estrogen receptor beta (ERβ) agonist, for vascular and cognitive aging. The study tested equol's effects on arterial stiffness, white matter lesions, and cognition. The multisite trial enrolled 369 self‐reported White and Black older adults aged 65 to 85 years. The trial investigated a novel dietary metabolite targeting ERβ pathways.

Schlagwörter

Stichwörter der Autor:innen

arterial stiffnesscognitive agingequolestrogen receptor betapreclinical Alzheimer's diseaserandomized controlled trialvascular agingwhite matter lesions

Autor:innen und Institutionen

  • Department of Epidemiology School of Public Health University of Pittsburgh Pittsburgh Pennsylvania USA.
  • Nell Hodgson Woodruff School of Nursing Emory University Atlanta Georgia USA.
  • Department of Medicine Center for Research on Health Care University of Pittsburgh Pittsburgh Pennsylvania USA.
  • Department of Psychiatry University of Pittsburgh Pittsburgh Pennsylvania USA.
  • Department of Neurological Surgery School of Medicine University of Pittsburgh Pittsburgh Pennsylvania USA.
  • Department of Neurology School of Medicine University of Pittsburgh Pittsburgh Pennsylvania USA.

ORCID-Profile: Akira Sekikawa

Förderung

  • NIA NIH HHS
  • NIDDK NIH HHS
  • NCATS NIH HHS
  • National Institute on Aging
  • National Institutes of Health
  • North Carolina Department of Health and Human Services

Zitieren

APA

Sekikawa, A., Wharton, W., Murray-Krezan, C., Wu, M., Chang, Y., Snitz, B. E., Coccari, M., Yang, S., Love, M. L., Cusick, D., Wang, R., Li, M., Park, C., Li, J., DeConne, T. M., Smith, C., Verble, D. D., Lancet, M. Q., Foroud, T., …, & Hughes, T. M. (2025). ACE trial design: Equol targeting estrogen receptor‐β in vascular and cognitive aging. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 11(3). https://doi.org/10.1002/trc2.70144

Vancouver

Sekikawa A, Wharton W, Murray-Krezan C, Wu M, Chang Y, Snitz BE, et al. ACE trial design: Equol targeting estrogen receptor‐β in vascular and cognitive aging. Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2025;11(3). doi:10.1002/trc2.70144

BibTeX
@article{Sekikawa2025,
  author = {Sekikawa, Akira and Wharton, Whitney and Murray-Krezan, Cristina and Wu, Minjie and Chang, Yuefang and Snitz, Beth E and Coccari, Mindy and Yang, Shaolin and Love, Monica L and Cusick, Deborah and Wang, Rongrong and Li, Mengyi and Park, Chloe and Li, Jiatong and DeConne, Theodore M and Smith, Carrie and Verble, Danielle D and Lancet, Michelle Quallich and Foroud, Tatiana and Kim, Tae and Nadkarni, Neelesh K and Mettenburg, Joseph M and Zamora, Ezequiel and Lopez, Oscar L and Hughes, Timothy M},
  title = {ACE trial design: Equol targeting estrogen receptor‐β in vascular and cognitive aging},
  journal = {Alzheimer's & Dementia: Translational Research & Clinical Interventions},
  year = {2025},
  volume = {11},
  number = {3},
  doi = {10.1002/trc2.70144}
}
Kostenlos starten →